Inhibition of DNA methyltransferase activity and expression by treatment with the pan-deacetylase inhibitor panobinostat in hepatocellular carcinoma cell lines

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Zopf, Steffen ^a   Ocker, Matthias ^d   Neureiter, Daniel ^b   Alinger, Beate ^b   Gahr, Susanne ^a,c   Neurath, Markus F ^a   Di Fazio, Pietro ^d  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

^c KLINIKUM NÜRNBERG   (Germany)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Deacetylase inhibitor; DNA methyltransferase; Epigenetics; Hepatocellular carcinoma; Transcriptional control

Indexed keywords

DNA METHYLTRANSFERASE; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; PANOBINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APC GENE; ARTICLE; CANCER CELL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DNA METHYLATION; DNA METHYLTRANSFERASE GENE; DOWN REGULATION; ENZYME INHIBITION; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RASSF1A GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DNA METHYLATION; DNA MODIFICATION METHYLASES; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INDOLES; LIVER NEOPLASMS; MALE; MICE; MICE, NUDE; TRANSPLANTATION, HETEROLOGOUS;

EID: 84865574682     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-386     Document Type: Article

References (63)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29. 10.3322/caac.20138, 22237781.
2. Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E, La Vecchia C. Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology 2008, 48:137-145. 10.1002/hep.22312, 18537177.
3. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576. 10.1053/j.gastro.2007.04.061, 17570226.
4. Duffy A, Greten T. Developing better treatments in hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2010, 4:551-560. 10.1586/egh.10.58, 20932140.
5. Hatziapostolou M, Iliopoulos D. Epigenetic aberrations during oncogenesis. Cell Mol Life Sci 2011, 68:1681-1702. 10.1007/s00018-010-0624-z, 21249513.
6. Park HJ, Yu E, Shim YH. DNA methyltransferase expression and DNA hypermethylation in human hepatocellular carcinoma. Cancer Lett 2006, 233:271-278. 10.1016/j.canlet.2005.03.017, 15885882.
7. Oh BK, Kim H, Park HJ, Shim YH, Choi J, Park C, Park YN. DNA methyltransferase expression and DNA methylation in human hepatocellular carcinoma and their clinicopathological correlation. Int J Mol Med 2007, 20:65-73.
8. Park IY, Sohn BH, Yu E, Suh DJ, Chung YH, Lee JH, Surzycki SJ, Lee YI. Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein. Gastroenterology 2007, 132:1476-1494. 10.1053/j.gastro.2007.01.034, 17408664.
9. Arora P, Kim EO, Jung JK, Jang KL. Hepatitis C virus core protein downregulates E-cadherin expression via activation of DNA methyltransferase 1 and 3b. Cancer Lett 2008, 261:244-252. 10.1016/j.canlet.2007.11.033, 18164808.
10. Zheng DL, Zhang L, Cheng N, Xu X, Deng Q, Teng XM, Wang KS, Zhang X, Huang J, Han ZG. Epigenetic modification induced by hepatitis B virus X protein via interaction with de novo DNA methyltransferase DNMT3A. J Hepatol 2009, 50:377-387. 10.1016/j.jhep.2008.10.019, 19070387.
11. Saito Y, Kanai Y, Nakagawa T, Sakamoto M, Saito H, Ishii H, Hirohashi S. Increased protein expression of DNA methyltransferase (DNMT) 1 is significantly correlated with the malignant potential and poor prognosis of human hepatocellular carcinomas. Int J Cancer 2003, 105:527-532. 10.1002/ijc.11127, 12712445.
12. Schneider-Stock R, Ocker M. Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors. IDrugs 2007, 10:557-561.
13. Donninger H, Vos MD, Clark GJ. The RASSF1A tumor suppressor. J Cell Sci 2007, 120:3163-3172. 10.1242/jcs.010389, 17878233.
14. Jain S, Chang TT, Hamilton JP, Lin SY, Lin YJ, Evans AA, Selaru FM, Lin PW, Chen SH, Block TM, et al. Methylation of the CpG sites only on the sense strand of the APC gene is specific for hepatocellular carcinoma. PLoS One 2011, 6:e26799. 10.1371/journal.pone.0026799, 3206845, 22073196.
15. Liu JB, Zhang YX, Zhou SH, Shi MX, Cai J, Liu Y, Chen KP, Qiang FL. CpG island methylator phenotype in plasma is associated with hepatocellular carcinoma prognosis. World J Gastroenterol 2011, 17:4718-4724. 10.3748/wjg.v17.i42.4718, 3237302, 22180715.
16. Saelee P, Wongkham S, Chariyalertsak S, Petmitr S, Chuensumran U. RASSF1A promoter hypermethylation as a prognostic marker for hepatocellular carcinoma. Asian Pac J Cancer Prev 2010, 11:1677-1681.
17. Honda S, Haruta M, Sugawara W, Sasaki F, Ohira M, Matsunaga T, Yamaoka H, Horie H, Ohnuma N, Nakagawara A, et al. The methylation status of RASSF1A promoter predicts responsiveness to chemotherapy and eventual cure in hepatoblastoma patients. Int J Cancer 2008, 123:1117-1125. 10.1002/ijc.23613, 18537155.
18. Quint K, Agaimy A, Di Fazio P, Montalbano R, Steindorf C, Jung R, Hellerbrand C, Hartmann A, Sitter H, Neureiter D, Ocker M. Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC. Virchows Arch 2011, 459:129-139. 10.1007/s00428-011-1103-0, 21713366.
19. Ocker M, Schneider-Stock R. Histone deacetylase inhibitors: signalling towards p21cip1/waf1. Int J Biochem Cell Biol 2007, 39:1367-1374. 10.1016/j.biocel.2007.03.001, 17412634.
20. Li D, Marchenko ND, Moll UM. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell Death Differ 2011, 18:1904-1913. 10.1038/cdd.2011.71, 3170683, 21637290.
21. Peng L, Seto E. Deacetylation of nonhistone proteins by HDACs and the implications in cancer. Handb Exp Pharmacol 2011, 206:39-56. 10.1007/978-3-642-21631-2_3, 21879445.
22. You JS, Kang JK, Lee EK, Lee JC, Lee SH, Jeon YJ, Koh DH, Ahn SH, Seo DW, Lee HY, et al. Histone deacetylase inhibitor apicidin downregulates DNA methyltransferase 1 expression and induces repressive histone modifications via recruitment of corepressor complex to promoter region in human cervix cancer cells. Oncogene 2008, 27:1376-1386. 10.1038/sj.onc.1210776, 17828306.
23. Xiong Y, Dowdy SC, Podratz KC, Jin F, Attewell JR, Eberhardt NL, Jiang SW. Histone deacetylase inhibitors decrease DNA methyltransferase-3B messenger RNA stability and down-regulate de novo DNA methyltransferase activity in human endometrial cells. Cancer Res 2005, 65:2684-2689. 10.1158/0008-5472.CAN-04-2843, 15805266.
24. Prince HM, Bishton MJ, Johnstone RW. Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncol 2009, 5:601-612. 10.2217/fon.09.36, 19519200.
25. Di Fazio P, Schneider-Stock R, Neureiter D, Okamoto K, Wissniowski T, Gahr S, Quint K, Meissnitzer M, Alinger B, Montalbano R, et al. The pan-deacetylase inhibitor panobinostat inhibits growth of hepatocellular carcinoma models by alternative pathways of apoptosis. Cell Oncol 2010, 32:285-300.
26. Neureiter D, Zopf S, Leu T, Dietze O, Hauser-Kronberger C, Hahn EG, Herold C, Ocker M. Apoptosis, proliferation and differentiation patterns are influenced by Zebularine and SAHA in pancreatic cancer models. Scand J Gastroenterol 2007, 42:103-116. 10.1080/00365520600874198, 17190770.
27. Moribe T, Iizuka N, Miura T, Kimura N, Tamatsukuri S, Ishitsuka H, Hamamoto Y, Sakamoto K, Tamesa T, Oka M. Methylation of multiple genes as molecular markers for diagnosis of a small, well-differentiated hepatocellular carcinoma. Int J Cancer 2009, 125:388-397. 10.1002/ijc.24394, 19384946.
28. Zopf S, Neureiter D, Bouralexis S, Abt T, Glaser KB, Okamoto K, Ganslmayer M, Hahn EG, Herold C, Ocker M. Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo. Int J Oncol 2007, 31:1391-1402.
29. Shen J, Wang S, Zhang YJ, Kappil M, Wu HC, Kibriya MG, Wang Q, Jasmine F, Ahsan H, Lee PH, et al. Genome-wide DNA methylation profiles in hepatocellular carcinoma. Hepatology 2012, 55:1799-1808. 10.1002/hep.25569, 22234943.
30. Lambert MP, Paliwal A, Vaissiere T, Chemin I, Zoulim F, Tommasino M, Hainaut P, Sylla B, Scoazec JY, Tost J, Herceg Z. Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intake. J Hepatol 2011, 54:705-715. 10.1016/j.jhep.2010.07.027, 21146512.
31. Um TH, Kim H, Oh BK, Kim MS, Kim KS, Jung G, Park YN. Aberrant CpG island hypermethylation in dysplastic nodules and early HCC of hepatitis B virus-related human multistep hepatocarcinogenesis. J Hepatol 2011, 54:939-947. 10.1016/j.jhep.2010.08.021, 21145824.
32. Hu L, Chen G, Yu H, Qiu X. Clinicopathological significance of RASSF1A reduced expression and hypermethylation in hepatocellular carcinoma. Hepatol Int 2010, 4:423-432. 10.1007/s12072-010-9164-8, 2836437, 20305761.
33. Kondo Y, Shen L, Suzuki S, Kurokawa T, Masuko K, Tanaka Y, Kato H, Mizuno Y, Yokoe M, Sugauchi F, et al. Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas. Hepatol Res 2007, 37:974-983. 10.1111/j.1872-034X.2007.00141.x, 17584191.
34. Yeo W, Wong N, Wong WL, Lai PB, Zhong S, Johnson PJ. High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma. Liver Int 2005, 25:266-272. 10.1111/j.1478-3231.2005.01084.x, 15780049.
35. Csepregi A, Rocken C, Hoffmann J, Gu P, Saliger S, Muller O, Schneider-Stock R, Kutzner N, Roessner A, Malfertheiner P, Ebert MP. APC promoter methylation and protein expression in hepatocellular carcinoma. J Cancer Res Clin Oncol 2008, 134:579-589. 10.1007/s00432-007-0321-y, 2757596, 17973119.
36. Lee S, Lee HJ, Kim JH, Lee HS, Jang JJ, Kang GH. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol 2003, 163:1371-1378. 10.1016/S0002-9440(10)63495-5, 1868296, 14507645.
37. Yu J, Ni M, Xu J, Zhang H, Gao B, Gu J, Chen J, Zhang L, Wu M, Zhen S, Zhu J. Methylation profiling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis. BMC Cancer 2002, 2:29. 10.1186/1471-2407-2-29, 139988, 12433278.
38. Yang B, Guo M, Herman JG, Clark DP. Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol 2003, 163:1101-1107. 10.1016/S0002-9440(10)63469-4, 1868243, 12937151.
39. Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, Factor VM, Thorgeirsson SS. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 2006, 130:1117-1128. 10.1053/j.gastro.2006.01.006, 16618406.
40. Venturelli S, Berger A, Weiland T, Zimmermann M, Hacker S, Peter C, Wesselborg S, Konigsrainer A, Weiss TS, Gregor M, et al. Dual antitumour effect of 5-azacytidine by inducing a breakdown of resistance-mediating factors and epigenetic modulation. Gut 2011, 60:156-165. 10.1136/gut.2010.208041, 21106551.
41. Hirasawa Y, Arai M, Imazeki F, Tada M, Mikata R, Fukai K, Miyazaki M, Ochiai T, Saisho H, Yokosuka O. Methylation status of genes upregulated by demethylating agent 5-aza-2'-deoxycytidine in hepatocellular carcinoma. Oncology 2006, 71:77-85.
42. Gahr S, Wissniowski T, Zopf S, Strobel D, Pustowka A, Ocker M. Combination of the deacetylase inhibitor panobinostat and the multi-kinase inhibitor sorafenib for the treatment of metastatic hepatocellular carcinoma - review of the underlying molecular mechanisms and first case report. J Cancer 2012, 3:158-165. 3328781, 22514558.
43. Ocker M, Alajati A, Ganslmayer M, Zopf S, Luders M, Neureiter D, Hahn EG, Schuppan D, Herold C. The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells. J Cancer Res Clin Oncol 2005, 131:385-394. 10.1007/s00432-004-0664-6, 15754201.
44. Herold C, Ganslmayer M, Ocker M, Hermann M, Geerts A, Hahn EG, Schuppan D. The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J Hepatol 2002, 36:233-240.
45. Ocker M. Deacetylase inhibitors - focus on non-histone targets and effects. World J Biol Chem 2010, 1:55-61. 10.4331/wjbc.v1.i5.55, 3083950, 21540990.
46. Du Z, Song J, Wang Y, Zhao Y, Guda K, Yang S, Kao HY, Xu Y, Willis J, Markowitz SD, et al. DNMT1 stability is regulated by proteins coordinating deubiquitination and acetylation-driven ubiquitination. Sci Signal 2010, 3:ra80. 10.1126/scisignal.2001462, 3116231, 21045206.
47. Peng L, Yuan Z, Ling H, Fukasawa K, Robertson K, Olashaw N, Koomen J, Chen J, Lane WS, Seto E. SIRT1 deacetylates the DNA methyltransferase 1 (DNMT1) protein and alters its activities. Mol Cell Biol 2011, 31:4720-4734. 10.1128/MCB.06147-11, 3232929, 21947282.
48. Zhou Q, Agoston AT, Atadja P, Nelson WG, Davidson NE. Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells. Mol Cancer Res 2008, 6:873-883. 10.1158/1541-7786.MCR-07-0330, 3361136, 18505931.
49. Januchowski R, Dabrowski M, Ofori H, Jagodzinski PP. Trichostatin A down-regulate DNA methyltransferase 1 in Jurkat T cells. Cancer Lett 2007, 246:313-317. 10.1016/j.canlet.2006.03.010, 16624484.
50. Fiskus W, Buckley K, Rao R, Mandawat A, Yang Y, Joshi R, Wang Y, Balusu R, Chen J, Koul S, et al. Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells. Cancer Biol Ther 2009, 8:939-950. 10.4161/cbt.8.10.8213, 2775142, 19279403.
51. Rhee I, Jair KW, Yen RW, Lengauer C, Herman JG, Kinzler KW, Vogelstein B, Baylin SB, Schuebel KE. CpG methylation is maintained in human cancer cells lacking DNMT1. Nature 2000, 404:1003-1007. 10.1038/35010000, 10801130.
52. Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE, Cui H, Feinberg AP, Lengauer C, Kinzler KW, et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002, 416:552-556. 10.1038/416552a, 11932749.
53. Lee EM, Shin S, Cha HJ, Yoon Y, Bae S, Jung JH, Lee SM, Lee SJ, Park IC, Jin YW, An S. Suberoylanilide hydroxamic acid (SAHA) changes microRNA expression profiles in A549 human non-small cell lung cancer cells. Int J Mol Med 2009, 24:45-50.
54. Delcuve GP, Khan DH, Davie JR. Roles of histone deacetylases (HDACs) in epigenetic regulation: emerging paradigms from studies with inhibitors. Clin Epigenetics 2012, 4:5. 10.1186/1868-7083-4-5, 3320549, 22414492.
55. Sampath D, Liu C, Vasan K, Sulda M, Puduvalli VK, Wierda WG, Keating MJ. Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia. Blood 2012, 119:1162-1172. 10.1182/blood-2011-05-351510, 22096249.
56. Di Fazio P, Montalbano R, Neureiter D, Alinger B, Schmidt A, Merkel AL, Quint K, Ocker M. Downregulation of HMGA2 by the pan-deacetylase inhibitor panobinostat is dependent on hsa-let-7b expression in liver cancer cell lines. Exp Cell Res 2012, 318:1832-1843. 10.1016/j.yexcr.2012.04.018, 22683924.
57. Braconi C, Huang N, Patel T. MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology 2010, 51:881-890.
58. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, Liu S, Alder H, Costinean S, Fernandez-Cymering C, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A 2007, 104:15805-15810. 10.1073/pnas.0707628104, 2000384, 17890317.
59. Zhang Z, Tang H, Wang Z, Zhang B, Liu W, Lu H, Xiao L, Liu X, Wang R, Li X, et al. MiR-185 targets the DNA methyltransferases 1 and regulates global DNA methylation in human glioma. Mol Cancer 2011, 10:124. 10.1186/1476-4598-10-124, 3193026, 21962230.
60. Pan W, Zhu S, Yuan M, Cui H, Wang L, Luo X, Li J, Zhou H, Tang Y, Shen N. MicroRNA-21 and microRNA-148a contribute to DNA hypomethylation in lupus CD4+ T cells by directly and indirectly targeting DNA methyltransferase 1. J Immunol 2010, 184:6773-6781. 10.4049/jimmunol.0904060, 20483747.
61. Denis H, Ndlovu MN, Fuks F. Regulation of mammalian DNA methyltransferases: a route to new mechanisms. EMBO Rep 2011, 12:647-656. 10.1038/embor.2011.110, 3128952, 21660058.
62. Rhodes LV, Nitschke AM, Segar HC, Martin EC, Driver JL, Elliott S, Nam SY, Li M, Nephew KP, Burow ME, Collins-Burow BM. The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells. Oncol Rep 2012, 27:10-16.
63. Choi MS, Shim YH, Hwa JY, Lee SK, Ro JY, Kim JS, Yu E. Expression of DNA methyltransferases in multistep hepatocarcinogenesis. Hum Pathol 2003, 34:11-17. 10.1053/hupa.2003.5, 12605361.